Erlinsbach

Researchers are evaluating the safety and tolerability of TAK-861 in people with narcolepsy type 1 (NT1) who have already been exposed to TAK-861 in earlier studies. The study also aims to observe improvements in symptoms such as excessive daytime sleepiness and the frequency of cataplexy episodes. This long-term extension trial continues from previous phase 2 and phase 3 trials and includes participants who completed those earlier studies. All participants in this trial will receive TAK-861 tablets. Those who were previously given a placebo in parent trials will be randomly assigned to a dose of TAK-861. The study plans to enroll up to 500 participants worldwide and will last approximately 5 years, or until the study is stopped or the drug is approved and launched. Participants will visit clinics multiple times, with some visits possibly done at home, and will have a follow-up check 4 weeks after their last dose. During the study, participants will be monitored for treatment-emergent adverse events from the time they consent until 4 weeks after their final dose, covering up to about 5 years. Researchers will assess safety and tolerability regularly through these visits and follow-ups. The focus is on identifying any side effects and understanding the long-term effects of TAK-861 in people with NT1.

Non-small cell lung cancer (NSCLC) survivors often experience ongoing physical and psychological challenges, including fatigue and breathing difficulties, which reduce their overall health-related quality of life (HRQoL). This research evaluates whether a digital lifestyle intervention can improve HRQoL in these survivors over three months. The study focuses on enhancing physical activity, nutrition, and breathing or relaxation practices through a mobile application designed specifically for NSCLC survivors. Participants in the intervention group will receive access to a personalized and interactive mobile app for three months after completing rehabilitation or cancer treatment. The program includes behavior change techniques such as goal setting, feedback, knowledge shaping, and behavior comparison. A single virtual session at the start helps participants familiarize themselves with the app and sets their program level. There are no face-to-face appointments during the intervention period. Throughout the study, researchers will monitor participants' health-related quality of life from the start until three months later. Participants must have access to a smartphone or tablet and understand German to follow the study materials and assessments. Data collection includes self-reported outcomes via the app, and safety and participation are overseen by the study team. The total involvement lasts for the three-month intervention period after treatment or rehabilitation completion.

Researchers are investigating the effects of eccentric cycling exercise (ECC) during pulmonary rehabilitation for patients with cardiopulmonary diseases. ECC allows training with low metabolic demands and has shown promise in improving muscle strength, walking distance, and oxygen uptake in patients with chronic obstructive pulmonary disease, heart failure, and coronary heart disease. This study aims to evaluate whether ECC can improve exercise capacity and possibly hemodynamics during prolonged rehabilitation programs for patients with pulmonary vascular disease and other cardiopulmonary conditions. Participants will be assigned to either perform ECC or receive standard cycling exercise as part of their cardiopulmonary rehabilitation. The ECC group performs eccentric cycling exercise while the standard care group undergoes usual rehabilitation care. Both groups receive their respective exercises in addition to regular rehabilitation treatments. The study evaluates the effects over a three-week rehabilitation period. During the study, participants' peak exercise performance will be measured before the intervention and immediately after the three-week rehabilitation. Researchers will monitor exercise capacity and related health outcomes to assess the impact of ECC compared to standard care. The study includes adults aged 18 to 85 with stable medication and no resting hypoxemia, with ongoing safety and progress assessments during rehabilitation.

This research aims to explore the effects of eccentric cycling exercise (ECC) during prolonged rehabilitation in patients with pulmonary vascular disease (PVD), including pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). ECC is studied because it allows for high-intensity training with low metabolic cost, which may improve exercise capacity and potentially impact heart function in this patient group. Previous studies have shown ECC to be feasible and well-tolerated by PVD patients and beneficial in other conditions like COPD and heart failure. The study compares two types of rehabilitation: one with eccentric cycling exercise where patients use a specially designed eccentric bike, and a normal rehabilitation program with standard cycling exercise. Patients will participate in their assigned rehabilitation program, allowing investigators to assess the effects of ECC compared to usual care. The study includes adults aged 18 to 85 years who have stable medication and no resting low oxygen levels. Participants will be monitored through various assessments during the rehabilitation period, focusing particularly on their peak exercise capacity measured after 3 weeks. Researchers will also observe possible improvements in exercise tolerance and heart function. The study’s timeline and evaluations are designed to determine whether ECC provides better outcomes during rehabilitation for PVD patients than traditional exercise methods.